Pharmacogenetics and breast cancer management: current status and perspectives.

about

Actionable pharmacogenetic markers for prediction and prognosis in breast cancer.Point-of-care devices: the next frontier in personalized chemotherapy.Pharmacogenetics of response to neoadjuvant paclitaxel treatment for locally advanced breast cancer.

P2860

Q35879741-805F6283-9BD8-4E0F-AF51-362616986C59 Q42353648-1B971894-0B89-4586-B411-D9EDEC073A80 Q47241273-983C6FF0-58FA-4611-8C62-282291F31B35

P2860

Pharmacogenetics and breast cancer management: current status and perspectives.

Item

http://www.wikidata.org/entity/Q38358816

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh

2015年學術文章

@zh-hant

name

Pharmacogenetics and breast cancer management: current status and perspectives.

@en

type

Item

label

Pharmacogenetics and breast cancer management: current status and perspectives.

@en

prefLabel

Pharmacogenetics and breast cancer management: current status and perspectives.

@en

P1476

Pharmacogenetics and breast cancer management: current status and perspectives.

@en

P2093

Cindy Serdjebi

http://www.w3.org/2001/XMLSchema#string

Gérard Milano

http://www.w3.org/2001/XMLSchema#string

Joseph Ciccolini

http://www.w3.org/2001/XMLSchema#string

Raphaelle Fanciullino

http://www.w3.org/2001/XMLSchema#string

P2860

A case-control study of the HER2 Ile655Val polymorphism in relation to risk of invasive breast cancer

Pharmacogenomics of breast cancer therapy: an update

Association study of genetic polymorphism in ABCC4 with cyclophosphamide-induced adverse drug reactions in breast cancer patients

Severe or lethal toxicities upon capecitabine intake: is DPYD genetic polymorphism the ideal culprit?

Profiling dihydropyrimidine dehydrogenase deficiency in patients with cancer undergoing 5-fluorouracil/capecitabine therapy

Common variants in genes coding for chemotherapy metabolizing enzymes, transporters, and targets: a case-control study of contralateral breast cancer risk in the WECARE Study.

Toxic death-case after capecitabine + oxaliplatin (XELOX) administration: probable implication of dihydropyrimidine deshydrogenase deficiency.

Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients.

CYP2D6 polymorphisms as predictors of outcome in breast cancer patients treated with tamoxifen: expanded polymorphism coverage improves risk stratification.

Advances in managing breast cancer: a clinical update

P304

719-729

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/17425255.2015.1008447

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-02-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25690018

http://www.w3.org/2001/XMLSchema#string

Pharmacogenetics and breast cancer management: current status and perspectives.

about

P2860

P2860

Pharmacogenetics and breast cancer management: current status and perspectives.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698